ZYNEのチャート
ZYNEの企業情報
| symbol | ZYNE |
|---|---|
| 会社名 | Zynerba Pharmaceuticals Inc （ジナ―バ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ジナーバ・ファーマスーティカル(Zynerba Pharmaceuticals Inc.)は専門的医薬品会社である。同社は患者のための経皮合成カンナビノイド治療法の開発・商業化に従事する。開発パイプラインには、ZYN002とZYN001という2つの製品候補が含まれる。ZYN002は非精神活性カンナビノイドである合成カンナビジオール（CBD）であり、特許保護された浸透増強ゲルとして皮膚を通って循環系に入る。ZYN002は難治性てんかん患者、変形性膝関節症患者、脆弱X症候群患者の第Ⅱ相臨床開発段階にある。ZYN001はパッチを通じて循環系への経皮送達を可能にするテトラヒドロカンナビノール（THC）のプロドラッグである。ZYN001は2つの疼痛適応症、線維筋痛症及び末梢神経障害性疼痛を標的とする。 ジナ―バ・ファ―マシュ―ティカルズは米国の特殊医薬品企業。主に、経皮吸収型薬剤デリバリ―システムの開発、商品化に従事する。合成カンナビノイドを利用し、薬剤抵抗性てんかん、脆弱エックス症候群、骨関節炎、線維筋痛、末梢性神経障害性疼痛などの治療に対する薬剤「ZYN002」や「ZYN001」を開発する。本社はペンシルベニア州。 Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. |
| 本社所在地 | 80 W. Lancaster Avenue Suite 300 Devon PA 19333 USA |
| 代表者氏名 | Armando Anido アルマンドアニード |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 484-581-7505 |
| 設立年月日 | 39083 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 22人 |
| url | www.zynerba.com |
| nasdaq_url | https://www.nasdaq.com/symbol/zyne |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -41.02128 |
| 終値（lastsale） | 7.37 |
| 時価総額（marketcap） | 129887944.01 |
| 時価総額 | 時価総額（百万ドル） 125.83440 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 82.71935 |
| 当期純利益 | 当期純利益（百万ドル） -40.74337 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Zynerba Pharmaceuticals Inc revenues was not reported. Net loss increased 56% to $24.3M. Higher net loss reflects Foreign exchange (loss) gain decrease from $285K (income) to $309K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.24 to -$1.80. |
ZYNEのテクニカル分析
ZYNEのニュース
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference 2023/03/01 12:00:00 GlobeNewswire
DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at Cowen’s 43 rd Annual Health Care Conference on Wednesday, March 8, 2023, at 2:50 p.m. ET, and host investor meetings. The conference is being held at the Boston Marriott Copley Place in Boston, Mass.
Momentum Technology Stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Codiak BioSciences, Inc. (NASDAQ:CDAK) 2023/02/21 14:32:58 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Momentum Technology Stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Codiak BioSciences, Inc. (NASDAQ:CDAK) appeared first on Stocks Equity .
Ensnaring stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -7.02%), Codiak BioSciences, Inc. (NASDAQ:CDAK -6.64%) 2023/02/21 12:56:57 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Ensnaring stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -7.02%), Codiak BioSciences, Inc. (NASDAQ:CDAK -6.64%) appeared first on Stocks Equity .
Have you been able to find a good deal on Zynerba Pharmaceuticals Inc.’s shares? 2023/02/15 16:08:00 US Post News
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) marked $0.57 per share on Tuesday, down from a previous closing price of $0.58. While Zynerba Pharmaceuticals Inc. has underperformed by -1.78%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ZYNE fell by -78.50%, with highs and lows ranging from $2.83 to […]
These strategies will help Zynerba Pharmaceuticals Inc. (ZYNE) succeed 2023/02/08 13:00:00 US Post News
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) closed Tuesday at $0.63 per share, up from $0.61 a day earlier. While Zynerba Pharmaceuticals Inc. has overperformed by 2.66%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ZYNE fell by -76.55%, with highs and lows ranging from $2.94 to $0.49, whereas […]
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference 2022/09/22 11:00:00 GlobeNewswire
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings. The conference is being held at the Sofitel New York in New York City.
Overwhelming stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -3.48%), InspireMD, Inc. (NASDAQ:NSPR -0.57%) 2022/09/16 00:14:47 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Overwhelming stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -3.48%), InspireMD, Inc. (NASDAQ:NSPR -0.57%) appeared first on Stocks Equity .
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium 2022/09/08 13:15:00 GlobeNewswire
INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile
Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/06 11:00:00 ForexTV
DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, … The post Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference appeared first on ForexTV .
Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium 2022/08/31 11:00:00 GlobeNewswire
DEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24 th International Research Symposium, which will be held in Oslo, Norway, September 8-10, 2022. A copy of the presentation slides will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/ . Additional meeting information can be found on the SSBP website at https://ssbp.org.uk/ .
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference 2022/09/22 11:00:00 GlobeNewswire
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings. The conference is being held at the Sofitel New York in New York City.
Overwhelming stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -3.48%), InspireMD, Inc. (NASDAQ:NSPR -0.57%) 2022/09/16 00:14:47 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Overwhelming stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -3.48%), InspireMD, Inc. (NASDAQ:NSPR -0.57%) appeared first on Stocks Equity .
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium 2022/09/08 13:15:00 GlobeNewswire
INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile
Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/06 11:00:00 ForexTV
DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, … The post Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference appeared first on ForexTV .
Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium 2022/08/31 11:00:00 GlobeNewswire
DEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24 th International Research Symposium, which will be held in Oslo, Norway, September 8-10, 2022. A copy of the presentation slides will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/ . Additional meeting information can be found on the SSBP website at https://ssbp.org.uk/ .